Results 21 to 30 of about 8,469 (207)
Indian Journal of Endocrinology and Metabolism, 2011 Management of prolactinoma in pregnancy is a big challenge for the treating obstetrician as prolactin levels are normally raised in pregnancy and this creates a possibility of missing the diagnosis of prolactinoma.
Sukhwinder Kaur Bajwa +3 more
doaj +1 more source
PBK/TOPK Inhibitor Suppresses the Progression of Prolactinomas
Frontiers in Endocrinology, 2022 BackgroundProlactinoma is the most common type of pituitary tumors, and its resultant tumor occupying and hormone disturbance greatly damage the health of patients.
Kejing Zhu +10 more
doaj +1 more source
International Clinical Neuroscience Journal, 2020 Instruction: The current study reports a woman with pituitary adenoma and frontal convexity meningioma that was detected accidentally. To the best of our knowledge, this case is considered as a rare clinical scenario.
Thi Phuong Hoai Dinh +2 more
doaj +1 more source
Late presentation of acromegaly in medically controlled prolactinoma patients
Endocrinology, Diabetes & Metabolism Case Reports, 2016 Co-secretion of growth hormone (GH) and prolactin (PRL) from a single pituitary adenoma is common. In fact, up to 25% of patients with acromegaly may have PRL co-secretion.
Ekaterina Manuylova +6 more
doaj +1 more source
Indian Journal of Endocrinology and Metabolism, 2021 Cabergoline has long been used in the medical management of prolactin-secreting pituitary adenomas. However, there is contradicting and inadequate evidence on the efficacy of cabergoline in achieving radiological and biochemical remission in prolactinoma.
Rakesh Mishra +5 more
doaj +1 more source
Menstrual cycle abnormalities in patients with prolactinoma and drug-induced hyperprolactinemia
Indian Journal of Endocrinology and Metabolism, 2017 Background and Objective: Hyperprolactinemia affects the reproductive endocrine axis; however, the degree of dysfunction may vary depending on etiology.
Bindu Kulshreshtha +6 more
doaj +1 more source
Anti-c-myc efficacy block EGFL7 induced prolactinoma tumorigenesis
Open Chemistry, 2019 Resistance to Dopamine agonists therapy is still a key factor that hinders the clinical treatment of prolactinoma. Consequently, a large number of investigations have been carried out to identify novel therapeutic targets.
Lan Xiaolei +4 more
doaj +1 more source
Annals of Medicine, 1998 The objectives of the treatment of hyperprolactinaemia are to suppress excessive hormone secretion and its clinical consequences, to remove tumour mass, to preserve the residual pituitary function and to prevent disease recurrence or progression. Prior to the advent of pharmacotherapy, therapy usually consisted of surgical resection and/or pituitary ...
COLAO, ANNAMARIA +2 more
openaire +4 more sources
Cabergoline Use and Pregnancy Outcomes: A Systematic Review. [PDF]
Birth Defects ResABSTRACT Introduction Lack of available expert guidelines leads clinicians to interrupt cabergoline treatment upon confirmation of pregnancy and consider switching to bromocriptine, which is more commonly used during pregnancy but is poorly tolerated.
Otis AS +4 more
europepmc +2 more sources
Increased Lipid Levels Improves after Treatment with Cabergolin in Patients with Prolactinoma
Medicine Science, 2015 It has been suggested that hyperprolactinemia may be associated with obesity and dyslipidemia. However it is not fully understood that dyslipidemia is occurs independently or due to obesity.
Mazhar Muslum Tuna +5 more
doaj +1 more source